Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Untreated Adult Acute Myeloid Leukemia: early-phase trial registry

1 of 13 indexed Untreated Adult Acute Myeloid Leukemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,315 of 28,707 conditions by registered trial count.

13 US clinical trials · 1 currently recruiting · #1,315 of 28,707 conditions by registered trial count

Untreated Adult Acute Myeloid Leukemia: 13 US clinical trials tracked, 1 recruiting.

Untreated Adult Acute Myeloid Leukemia is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 3 of these trials.

Enrollment posture brief

Registry condition untreated-adult-acute-myeloid-leukemia

OPEN 1 | RECR 8% | LATE 0 | EARLY 11 | RANK #1315 | SPON 3

Nearest open-share peer: Sinusitis (8% recruiting · 13 trials)

ACL Injury61.5%Acute Biphenotypic Leukemia46.2%Accidental Falls30.8%Actinic Keratoses23.1%Untreated Adult Acute My (th…8%
Open-enrollment share among volume-matched conditions near Untreated Adult Acute Myeloid Leukemia

Untreated Adult Acute Myeloid Leukemia lists 1 open slots (8% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Untreated Adult Acute Myeloid Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Untreated Adult Acute Myeloid Leukemia is recruiting below its size-band peers.

    1 of 13 indexed trials (7.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Untreated Adult Acute Myeloid Leukemia research.

    Fred Hutchinson Cancer Center accounts for 3 of 13 trials (23.1%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Untreated Adult Acute Myeloid Leukemia trials plan to enrol fewer than 100 people.

    Median target enrolment is 39 among the 13 trials that report a genuine target (sentinel values excluded). 10 of those (76.9%) plan for fewer than 100 participants.

  4. Untreated Adult Acute Myeloid Leukemia research is mostly interventional.

    12 interventional and 1 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 26

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 2 270 participants

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

NCT00801489

ACTIVE NOT RECRUITING Phase 2 57 participants

Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients

Wake Forest University Health Sciences

NCT02835222

ACTIVE NOT RECRUITING Phase 1 30 participants

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

City of Hope Medical Center

NCT03009240

COMPLETED Phase 2 546 participants

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

NCT00416598

COMPLETED Phase 1 199 participants

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Fred Hutchinson Cancer Center

NCT02044796

COMPLETED Phase 2 50 participants

Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

University of Washington

NCT01101880

COMPLETED Phase 2 39 participants

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT02583893

COMPLETED Phase 1 39 participants

Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS

Fred Hutchinson Cancer Center

NCT01141725

COMPLETED Phase 1 28 participants

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Fred Hutchinson Cancer Center

NCT02921061

COMPLETED 14 participants

Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia

Wake Forest University Health Sciences

NCT02581917

COMPLETED Phase 1 13 participants

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Bhavana Bhatnagar

NCT02323607

COMPLETED NA 12 participants

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

University of Washington

NCT02121418

COMPLETED Phase 2 12 participants

PXD101 in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

NCT00357032

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 6

Named interventions

Most-linked intervention names on Untreated Adult Acute Myeloid Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cytarabine Drug
8 trials
Laboratory Biomarker Analysis Other
6 trials
Decitabine Drug
5 trials
Daunorubicin Hydrochloride Drug
3 trials
Filgrastim Biological
2 trials
Cladribine Drug
2 trials
belinostat Drug
1 trials
Mitoxantrone Hydrochloride Drug
1 trials

US sites by state

Facility locations filed on Untreated Adult Acute Myeloid Leukemia trials. A trial with sites in several states counts in each.

Washington 5 trials
California 4 trials
North Carolina 2 trials
Virginia 1 trials
Texas 1 trials
Pennsylvania 1 trials
Ohio 1 trials
Montana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Untreated Adult Acute Myeloid Leukemia page

13 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Untreated Adult Acute Myeloid Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Fred Hutchinson Cancer Center sponsors the most Untreated Adult Acute Myeloid Leukemia trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Untreated Adult Acute Myeloid Leukemia condition card totals 13 registered trials; most-linked intervention Cytarabine; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.